RT Journal Article SR Electronic T1 Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1244 OP 1252 DO 10.2967/jnumed.112.109306 VO 53 IS 8 A1 Christian Buchbender A1 Till A. Heusner A1 Thomas C. Lauenstein A1 Andreas Bockisch A1 Gerald Antoch YR 2012 UL http://jnm.snmjournals.org/content/53/8/1244.abstract AB With integrated whole-body PET/MRI, a novel metabolic–anatomic imaging technique recently has been introduced into clinical practice. This review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. If PET/MRI literature is not yet available for some types of tumors, potential indications are based on available PET/CT and MRI data. PET/MRI seems to be of benefit in T-staging of primary bone tumors and soft-tissue sarcomas. With regard to N-staging, PET/MRI can be considered similarly accurate to PET/CT when applied as a whole-body staging approach. M-staging will benefit from MRI accuracy in the brain, the liver, and bone.